Regeneron, Amgen, and Novo Nordisk, the maker of Ozempic, are all in the race to develop new weight loss medications in response to the growing demand. This competition is intensifying as pharmaceutical companies seek to break the duopoly dominated by Novo Nordisk, which produces Ozempic and Wegovy, and Eli Lilly, the manufacturer of Zepbound. The surge in demand for these drugs has propelled Novo Nordisk and Eli Lilly into the ranks of the world’s most valuable pharmaceutical companies, with the potential to become the first $1 trillion firms.

Several drug manufacturers are now striving to develop their own weight loss solutions. Here’s a glimpse into the companies working on cutting-edge weight loss treatments:

Novo Nordisk
Novo Nordisk, known for Ozempic and Wegovy, is pioneering the weight loss drug revolution. They have announced the development of a new pill called Amycretin, which demonstrated impressive weight loss results of 13% after 12 weeks in early trials, surpassing the outcomes of both Wegovy and Ozempic.

Eli Lilly Rivaling
Novo Nordisk, Eli Lilly is also venturing into the weight loss medication arena with their oral drug, Orforglipron. Early trials have shown promising results, with users achieving nearly 15% weight loss after 36 weeks.

Viking Therapeutics
Based in San Diego, Viking Therapeutics has reported encouraging results for its new weight loss drug, demonstrating an average weight loss of 14% after 13 weeks of treatment compared to a placebo.

Zealand Pharma
Teaming up with Boehringer Ingelheim, Zealand Pharma is developing survodutide, showing significant improvements in treating obesity and a liver condition known as MASH in phase-two trials. Previous studies have indicated a weight loss of nearly 15% over 46 weeks.

MariTide
MariTide, also known as AMG 133, exhibits promising results in early trials, offering up to 15% reduction in body weight after just 85 days with a monthly dose, unlike Wegovy and Zepbound, which require weekly doses.

Roche
Having acquired Carmot Therapeutics, Roche aims to revolutionize weight loss medications with CT-388, demonstrating an approximate loss of 17 pounds after four weeks in initial trials.

Regeneron
Regeneron Exploring genetic insights, Regeneron is investigating new antibody treatments to counteract muscle loss associated with weight loss drugs like Wegovy, while also focusing on genetic factors influencing obesity.